Bioptigen Releases Envisu R4300 SD-OCT Deep Imaging at ARVO

Bioptigen Inc. (Research Triangle Park, NC) introduced the Envisu R4300, the deepest spectral domain optical coherence tomography imaging system for preclinical applications, according to a company news release.

The Envisu R4300 is reportedly the first fourier-domain optical coherence tomography system with extended depth-imaging capability in the 800-nm wavelength band. With an imaging depth of 8 mm and better than 5-µm axial resolutions, the Envisu R4300 is designed for imaging deep eye structures for preclinical ophthalmic research and development. Its convertible objective lens system provides extended-depth and high-resolution retinal imaging for visualization of outer retinal structures, the choroid, and deep structures of the optic nerve head.

For more information, visit bioptigen.com.

Volk Introduces ROLS Infinity for Viewing Reinverted Retinal Images

Volk Optical, Inc. (Mentor, OH), released the ROLS Infinity viewing system for reinverted images during vitreoretinal surgery. Used to correctly orient the images created by noncontact viewing systems or contact lenses, the ROLS Infinity delivers precise image reproduction for visualization of the macula and panoramic views up to the ora serrata, according to a company news release.

The unit’s low-profile design minimizes the microscope’s stack height. The ROLS Infinity is available in a manual configuration or a foot switch-operated powered version. When combined with Volk’s modular Merlin surgical viewing system, the Infinity’s high magnification and wide-field vitrectomy lenses reportedly form an advanced method for noncontact retinal viewing.

For more information, visit volk.com.

AmeriSciences Releases OS2 Ocular Support Solution for Eye Disease

AmeriSciences (Houston, TX) introduced the OS2 Ocular Support Solution, a product designed to reduce the eye damage that comes with age or through exposure to ultraviolet radiation from the sun. OS2 has been statistically and clinically proven to neutralize cell-damaging free radicals and may help preserve visual and macular health, according to a company news release.

OS2 was developed by Thomas LoBue, MD, and scientists at the National Aeronautics and Space Administration to help patients with diabetes, macular degeneration, computer fatigue syndrome, glaucoma, dry eye, and other eye-related problems.

For more information, visit amerisience.com.

Optimedica Names New Vice President of Research and Development

OptiMedica Corp. (Santa Clara, CA) has named David D. Scott as its new vice president of research and development. Mr. Scott is a scientist and medical device executive with 18 years of engineering program management and product development experience. He will be responsible for driving OptiMedica’s new technology and product innovation, according to a company news release.

Prior to joining OptiMedica, Mr. Scott served as director of imaging systems at Intuitive Surgical (Sunnyvale, CA). His expertise spans a broad range of sophisticated medical technologies, including laser scanning systems, computed tomography, robotics, precision motion control, spectroscopy, imaging, signal processing, ultrasound, and x-ray computed tomography, according to the company.

ARVO Foundation for Eye Research Awards First Ludwig Von Sallman Clinician-Scientist Award

Karl Deisseroth, MD, PhD, has been named the first recipient of the Ludwig von Sallman Clinician-Scientist Award, presented by the ARVO Foundation for Eye Research to a clinician-scientist younger than 40 years. Dr. Deisseroth, associate professor of bioengineering and psychiatry at Stanford University, was recognized for his groundbreaking work in developing and using optogenetic approaches to study neuronal function.
“It is an honor to recognize the far-reaching impact Dr. Deisseroth’s technique has had on ophthalmology and vision science,” said Gary W. Abrams, MD, chair of the ARVO Foundation for Eye Research. “We have great expectations that his pioneering work will lead to real advances in understanding basic retinal function and the restoration of vision in the future.”

Ocusoft Introduces Ocupox Convenience Kit

Ocusoft, Inc. (Rosenberg, TX), introduced the prescription-only Ocupox Convenience Kit for the treatment of acute eyelid conditions. The Ocupox Convenience Kit contains Ocupox, Ocusoft Lid Scrub Plus Extra Strength Pre-Moistened Pads, and Tears Again advanced Liposome Spray. Each component in the Ocupox Convenience Kit was selected as a result of requests from doctors seeking a simple yet effective treatment option specific to acute cases of lid disease, according to a company news release. For more information, visit ocusoft.com.

Merz Pharmaceuticals Announces New Centers for Medicare and Medicaid Billing Q-code for Xeomin

Merz Pharmaceuticals, LLC (Greensboro, NC), announced that the Centers for Medicare & Medicaid Services has granted a unique Healthcare Common Procedure Coding System billing code, Q2040, for Xeomin (incobotulinumtoxinA). The company reported that the new code will help simplify the billing and reimbursement process for prescribers of Xeomin. The FDA approved Xeomin in 2010 for the treatment of adults with cervical dystonia to decrease the severity of abnormal head positioning and neck pain in both botulinum toxin-naive and previously treated patients as well as blepharospasm in adults who have been previously treated with Botox (Allergan, Inc.). For more information, visit xeomin.com.

INDEX OF ADVERTISERS

Allergan, Inc. COMBIGAN...........................................65, Cover 4
www.combigan.com

Allergan, Inc. LASTACAFT...........................................40, 41
www.allergan.com

Allergan, Inc. RESTASIS.............................................24, 25
www.allergan.com

Aton Pharma LACRISERT............................................Cover 2, 3
Phone (877) ATON-549
www.atonpharma.com

Bausch + Lomb Crystalens..........................................5
www.bausch.com

Bausch + Lomb ZIRGAN.............................................19
www.bausch.com

FCI Ophthalmics.............................................................6
Phone (800) 932-4202
www.fci-Ophthalmics.com

Inspire Pharmaceuticals............................................27, 28
www.AzaSite.com

ISTA Pharmaceuticals BEPREVE..............................15, 16
www.istavision.com

Lumenis, Inc...............................................................13
Phone (877) 586-3647
www.lumenis.com

Oculus, Inc...............................................................Cover 3
Phone (888) 284-8004
www.oculususa.com

This advertiser index is published as a convenience and not as part of the advertising contract. Although great care will be taken to index correctly, no allowance will be made for errors due to spelling, incorrect page number, or failure to insert.